Inventors at the University of Missouri have developed a pre-therapeutic modality to stimulate the immune system. Specifically, this modality targets human T-cells via CD3 potentiation to amplify the immune response produced against various persistent infections, such as human cytomegalovirus.
Human cytomegalovirus (HCMV) infects the population at high incidence, approximately 60% of adults in developed countries and 100% in developing countries. Infection is often asymptomatic and controlled by long-lasting T-cell responses driving the virus to latency. However, sterilizing immunity is not induced, which leaves a potential for reactivation. With recurrence, chronic inflammation and life-threatening disease can occur.
Limited effective approaches exist to target this highly prevalent virus. Through CD3 potentiation, the current invention enhances the expansion of both public and private T-cell clones, responding to antigen-presenting cells and immunodominant peptides from HCMV. This invention demonstrates a novel strategy for the prevention and treatment of HCMV and other chronic infectious diseases.
Can be used as alone or as an adjuvant to other immunotherapies
Enhances clonal expansion of several T-cell classes with a unique response pattern, depending on antigen weakness and T-cell receptor status
State of Development
Diana Gil Pages, Adam G. Schrum
Becher LRE, Nevala WK, Sutor SL, et al. Public and private human T-cell clones respond differentially to HCMV antigen when boosted by CD3 potentiation. Blood Adv. 2020;4(21):5343-5356.
Brian Buntaine, MS, MBA
Senior Manager, Technology Transfer
Name: Brian Buntaine, MS, MBA
Title: Senior Manager, Technology Transfer
Department: MU Technology Advancement Office
Address: Columbia, Missouri 65211